Targets › IRE1
1 program from 1 company in 1 trial: 1 Phase 3; Neurology; next expected readout Jan 2028.
Serine/threonine-protein kinase and endoribonuclease that acts as a key sensor for the endoplasmic reticulum unfolded protein response (UPR). In unstressed cells, the endoplasmic reticulum luminal domain is maintained in its inactive monomeric state by binding to the endoplasmic reticulum chaperone HSPA5/BiP. Accumulation of misfolded proteins in the endoplasmic reticulum causes release of HSPA5/BiP, allowing the…. (UniProt, O75460)
Open in Phaseline: the race on IRE1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| The George Institute | Deferoxamine Mesylate Iron chelator that reduces iron-mediated oxidative stress and secondary brain injury from | IRE1, FTH1 | Phase 3 | Intracerebral Hemorrhage | Jan 2028 |
Intracerebral Hemorrhage (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.